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Abstract
Background: Liver failure patients have traditionally been empirically transfused prior to invasive procedures. Blood
transfusion is associated with immunologic and nonimmunologic reactions, increased risk of adverse outcomes and
high costs. Scientific evidence supporting empirical transfusion is lacking, and the best approach for blood
transfusion prior to invasive procedures in cirrhotic patients has not been established so far.
The aim of this study is to compare three transfusion strategies (routine coagulation test-guided – ordinary or
restrictive, or thromboelastometry-guided) prior to central venous catheterization in critically ill patients with cirrhosis.
Methods/design: Design and setting: a double-blinded, parallel-group, single-center, randomized controlled clinical
trial in a tertiary private hospital in São Paulo, Brazil. Inclusion criteria: adults (aged 18 years or older) admitted to the
intensive care unit with cirrhosis and an indication for central venous line insertion. Patients will be randomly assigned
to three groups for blood transfusion strategy prior to central venous catheterization: standard coagulation tests-based,
thromboelastometry-based, or restrictive. The primary efficacy endpoint will be the proportion of patients transfused
with any blood product prior to central venous catheterization. The primary safety endpoint will be the incidence of
major bleeding. Secondary endpoints will be the proportion of transfusion of fresh frozen plasma, platelets and
cryoprecipitate; infused volume of blood products; hemoglobin and hematocrit before and after the procedure;
intensive care unit and hospital length of stay; 28-day and hospital mortality; incidence of minor bleeding; transfusion-
related adverse reactions; and cost analysis.
Discussion: This study will evaluate three strategies to guide blood transfusion prior to central venous line placement
in severely ill patients with cirrhosis. We hypothesized that thromboelastometry-based and/or restrictive protocols are
safe and would significantly reduce transfusion of blood products in this population, leading to a reduction in costs
and transfusion-related adverse reactions. In this manner, this trial will add evidence in favor of reducing empirical
transfusion in severely ill patients with coagulopathy.
Trial registration: ClinicalTrials.gov, identifier: NCT02311985. Retrospectively registered on 3 December 2014.
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Background
Central venous catheterization (CVC) is a routine pro-
cedure in the intensive care unit (ICU) [1]. In the USA
alone, more than 15 million catheter-days are reported
annually [2]. Bleeding is the most common complication
of CVC [3], with an incidence of between 12 per 1000
[4] and 94 per 1000 catheter insertions [5], and may be
life-threatening in severe cases. More recently, the use of
ultrasound guidance for CVC has significantly decreased
overall mechanical complication rates [6–10] and is safe
in patients with coagulopathy [11].
Patients with liver failure are classically believed to be
prone to bleeding disorders [12]. Currently, approxi-
mately 9 out of 10 ICU physicians empirically transfuse
liver failure patients before invasive procedures [13].
However, scientific evidence for this practice is lacking.
Recent medical literature evidence now shows that
patients with liver failure exhibit a rebalancing ability
between anticoagulant and procoagulant factors [12] and
have thrombin generation comparable to healthy indi-
viduals [14]. Thus, bleeding in those patients may be
mainly related to circulatory and endothelial alterations
instead of coagulation disorder per se. In spite of that,
several physicians rely on standard coagulation tests
(SCTs), i.e., prothrombin time (PT), international nor-
malized ratio (INR), activated partial thromboplastin
time (aPTT) and platelet count, to guide blood transfu-
sion before CVC in patients with cirrhosis [15, 16].
It has been shown that SCTs reflect a limited view of
coagulation status (isolated plasmatic component evalu-
ation) [17, 18] and do not accurately predict bleeding
risk in patients with suspected coagulopathy [18–21].
Specifically, patients with liver disease and prolonged
PT/aPTT may have coagulation factor levels above the
sufficient for adequate clot formation [22]. Moreover, at-
tempts to correct (or normalize) standard coagulation
tests by transfusion do not guarantee coagulopathy
reversal [23, 24] and to insist on this practice may
increase the risk of transfusion-related complications, in-
cluding death [25].
Rotational thromboelastometry (ROTEM®) is a point-
of-care test that evaluates coagulation according to the
viscoelastic properties of a whole blood sample [26].
ROTEM® has the advantage of a more comprehensive
(clot initiation, formation and stabilization) and faster
(online) bedside coagulation evaluation when compared
to SCTs [27]. Clinical protocols based on thromboelasto-
metry have been effective in reducing blood transfusion,
costs and mortality in diverse clinical settings [28–31]
including liver transplantation [32, 33].
General clinical practice guidelines recommend prophy-
lactic transfusion of blood products prior to invasive pro-
cedures based on SCTs alterations [34–36]. Nevertheless,
there is no consensus as to whether and how blood
transfusion should be used before invasive procedures,
particularly in patients with cirrhosis. The majority of
available data have originated from small clinical trials and
observational studies, which limit an evidence-based
approach. The culture of blood transfusion is moving to-
wards a rational evidence-based use of blood and its com-
ponents [37].
This study will compare three blood transfusion protocols
(coagulogram-based, thromboelastometry-based and re-
strictive) prior to CVC in critically ill patients with cirrhosis.
We hypothesized that restrictive and/or
thromboelastometry-guided transfusion protocols are safe
and would decrease the need of blood products transfusion
compared to an ordinary coagulogram-based protocol in
critically ill patients with cirrhosis submitted to a CVC.
Methods/design
Study design
This is a double-blinded, parallel-group, superiority,
single-center, randomized controlled clinical trial.
Study setting
The participating hospital is a private tertiary 657-bed
hospital in São Paulo, Brazil, with an active liver transplant
program (mean ± standard deviation (SD) 118 ± 15 liver
transplants per year). Patients will be screened and re-
cruited in two mixed medical-surgical intensive care units,
with 48 beds in total, and 3673 admissions per year.
Participants
All adult patients (aged 18 years or older) admitted to
the ICU with chronic liver failure and an indication for
bedside central venous line placement for intravenous
(I.V.) medication administration (including vasopres-
sors), hemodialysis and/or hemodynamic monitoring will
be eligible for inclusion. Chronic liver failure will be
defined as liver cirrhosis of any etiology diagnosed via
biopsy or clinical evaluation. The exclusion criteria will
be: acute liver failure, an indication for a peripherally
inserted central venous catheter, current use of orally ad-
ministered (e.g., inhibitors of factor Xa, thrombin and
vitamin K-dependent factors) or parenterally adminis-
tered anticoagulants (e.g., nonfractionated heparin or
low-molecular-weight heparin) in full therapeutic dos-
age, von Willebrand disease and enrollment in another
clinical trial with blood transfusion as intervention.
Laboratory procedures
Before a CVC, every included patient will be submitted to
blood sampling for SCTs (PT, INR, aPTT and platelet
count), ROTEM® analysis, serum fibrinogen, hemoglobin,
hematocrit, ionized calcium and arterial pH. Blood sam-
ples of 5 mL will be obtained directly from a peripheral
vein by applying a light tourniquet to avoid blood stasis,
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or from a central venous line after discarding the first
5 mL of blood (in the case of an indication for a second
CVC, e.g., hemodialysis catheter), or from an arterial line.
Blood samples for SCTs, ROTEM® and fibrinogen will be
conditioned in citrate tubes (3.2%; Sarstedt Monovette®,
Wedel, Germany) and processed immediately. Blood
samples for hemoglobin level, hematocrit and platelet
count will be conditioned in 2.6-mL tubes containing
EDTA KE (Sarstedt Monovette®, Wedel, Germany).
Thromboelastometry analysis (ROTEM® delta, Penta-
pharm Co., Munich, Germany) will be performed by pip-
etting 300 μL citrated whole blood and 20 μL 0.2-M
calcium chloride (CaCl2) with specific activators into a
plastic cup [38]. Extrinsically activated (EXTEM), intrin-
sically activated (INTEM), and fibrinogen polymerization
(FIBTEM) assays will be performed. ROTEM® analysis will
run for up to 60 min. The parameters coagulation time
(CT; s), clot formation time (CFT; s), maximum clot firm-
ness (MCF; mm), alpha angle (α; degrees) and amplitude
at 10 min (A10; mm) will be recorded [38].
The EXTEM assay contains a preparation of human re-
combinant tissue factor, which activates the coagulation
cascade and can assess coagulation status via CTEXTEM,
CFTEXTEM and MCFEXTEM [27]. The FIBTEM assay uses
cytochalasin D which is a potent platelet inhibitor and
serves to evaluate fibrinogen function and fibrin
polymerization [27]. The A10 is a surrogate marker of
MCF and can predict coagulopathy with high sensitivity
and specificity (1.0 and 0.7, respectively) with the advan-
tage of a faster evaluation of coagulation disorders [39].
Prothrombin time, INR and aPTT (ACL TOP 700 sys-
tem, Instrumentation Laboratory, Bedford, MA, USA),
serum fibrinogen (Clauss method) and platelet count
(Sysmex® XN-Series, Sysmex Corporation, Lincolnshire,
IL, USA) will be performed according to the hospital’s
standard analytical methods.
Central venous catheterization
All CVCs will be performed with real-time ultrasound
(Bard Site ~ Rite® 5 Ultrasound System, Bard Access
Systems, Salt Lake City, UT, USA) guidance, using the
modified Seldinger (over the guidewire) technique. Only
ICU physicians and medical residents trained in
ultrasound-guided vascular access will be allowed to per-
form the procedures. To obtain a valid training status,
the ICU physician must have performed at least 50
ultrasound-guided CVCs and at least 12 ultrasound-
guided insertions the previous year. The choice of inser-
tion site (jugular, femoral or subclavian) will be at the in-
serter’s discretion. All procedures will be performed
according to best practices guidelines [40] and audited
by a staff nurse. A chest X-ray will be ordered after each
procedure (except for femoral vein site) to assess
catheter positioning and complications. A blinded-to-
intervention nurse will inspect the insertion site for local
complications within the first 24 h after catheter place-
ment using the HEME tool checklist [41].
Inclusion in the trial does not preclude concomitant
care. The researchers will monitor whether patients will
receive any blood transfusion related to the procedure
within the first 24 h.
Interventions
Patients will be randomly assigned to three groups, each in-
cluding a protocol to guide blood product transfusion (fresh
frozen plasma (FFP), platelets and/or cryoprecipitate) prior
to CVC, namely: (1) a transfusion protocol based on stand-
ard coagulation tests – Coagulogram-based group, (2) a
transfusion protocol based on rotational thromboelastome-
try – Thromboelastometry-based group or (3) a restrictive
transfusion protocol – Restrictive group – also based on
SCTs, but with wider transfusion trigger values.
Coagulogram-based group
The Coagulogram-based group (control group) is based
on our institutional protocol and takes into account the
SCTs PT/INR, aPTT, platelet count and serum fibrino-
gen levels to guide transfusion prior to CVC (Fig. 1).
Accordingly, if INR ≤1.5, aPTT ≤50 s, platelet count
≥50,000/μL and serum fibrinogen ≥150 mg/dL, no trans-
fusion is indicated. Otherwise, if INR >1.5 or aPTT
>50 s, FFP is transfused at 10 mL per kg of body weight;
and/or if platelet count <50,000/μL, 1 unit per 10 kg of
body weight of random platelets (up to 10 units) or 1
unit of apheresis platelets is transfused; and/or if serum
fibrinogen <150 mg/dL, 1 unit per 10 kg of body weight
of cryoprecipitate is transfused (up to 10 units).
Thromboelastometry-based group
The thromboelastometry-based transfusion protocol uses
EXTEM and FIBTEM assays from the ROTEM® and was
adapted from Görlinger et al. [42] (Fig. 2). No transfusion
is necessary when CTEXTEM is ≤80 s and A10EXTEM is
≥40 mm. The CTEXTEM will be used to assess coagulation
factor deficiency. For patients in whom CTEXTEM is >80 s,
transfusion of 10 mL per kg of body weight of FFP is per-
formed. If the patient presents an A10EXTEM <40 mm, we
further evaluate the A10FIBTEM. If A10FIBTEM is ≥10 mm
(indicating adequate fibrinogen function), random platelet
units (1 unit per 10 kg of body weight; maximum 10 units)
or 1 unit of apheresis platelets is transfused. Otherwise, if
A10FIBTEM is <10 mm (indicating fibrinogen deficiency),
cryoprecipitate (1 unit per 10 kg of body weight; max-
imum 10 units) is transfused.
Restrictive group
The restrictive transfusion protocol is also based on
SCTs, but it uses wider transfusion triggers and it does
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not take into account serum fibrinogen and aPTT levels
(Fig. 3). If INR is ≤5.0 and platelet count is ≥25,000/μL,
no transfusion is required. If INR is >5.0, FFP is trans-
fused at 10 mL per kg of body weight; and/or platelet
count is <25,000/μL, random platelet units (1 unit per
10 kg of body weight; maximum 10 units) or 1 unit of
apheresis platelets is transfused.
Study endpoints
The primary efficacy endpoint is the proportion of
patients transfused with any blood product (i.e., FFP,
platelets or cryoprecipitate) prior to CVC. The
primary safety endpoint is the incidence of major
bleeding within the first 24 h after catheter insertion.
Major bleeding was defined according to the HEME
tool [41]. According to the HEME tool, major bleed-
ing is defined as overt bleeding with any of the fol-
lowing (in the absence of other causes): decrease in
hemoglobin of 20 g/L or more, transfusion of 2 or
more units of RBC with no increase in hemoglobin
level, decrease in systolic BP by 10 mmHg or more
while the patient is sitting up, spontaneous decrease
Fig. 1 Coagulogram-based blood transfusion protocol. INR international normalized ratio; aPTT activated thromboplastin time; FFP fresh frozen plasma
Fig. 2 Thromboelastometry-based blood transfusion protocol. CT clotting time; MCF maximum clot firmness; A10 amplitude at 10 min; FFP fresh
frozen plasma
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in systolic BP of 20 mmHg or more or increase in
heart rate by 20 bpm or more; bleeding at any one of
the following sites: intracranial, intraspinal, intraocu-
lar, pericardial, retroperitoneal or intraarticular; or
wound-related bleeding requiring an intervention.
The secondary efficacy endpoints will be: the propor-
tion of patients transfused with each blood component
and the infused volume of each blood component,
hemoglobin and hematocrit levels before and up to 24 h
after CVC, costs associated to blood product transfusion
and laboratory tests, ICU and hospital length of stay,
and ICU, 28-day and hospital mortality. Secondary safety
endpoints will include: the incidence of minor bleeding
complications (i.e., oozing or hematoma with no criteria
for major bleeding) and the proportion of patients trans-
fused due to bleeding within the first 24 h after CVC,
and the incidence of acute transfusion-related adverse
events (i.e., transfusion-associated cardiac overload,
acute hemolytic transfusion reactions, anaphylactic reac-
tions, febrile nonhemolytic reactions and urticarial reac-
tions). The transfusion of bleeding patients after CVC
will follow the Hospital Israelita Albert Einstein institu-
tional transfusion protocol. Accordingly, if INR >1.5 or
aPTT >32 s, FFP (10 mL per kg) is administered. If
serum fibrinogen <150 mg/dL, cryoprecipitate (1 unit
per 10 kg) or fibrinogen concentrate (2 to 4 g) is admin-
istered. If the platelet count <50 x 103/mm3, random
platelets (1 unit per 10 kg) or apheresis platelets (1 unit)
are administered. Correction of hypothermia (axillary
temperature ≥35 °C), hypocalcemia (ionized calcium
≥1.14 mmol/l) and acidosis (pH ≥7.31) is always
recommended.
Participant timeline and study flowchart
The participant timeline and study flowchart are presented
in Figs. 4 and 5, respectively. A filled Standard Protocol
Items: Recommendations for Interventional Trials (SPIRIT)
Checklist is available (see Additional file 1).
Recruitment
Patients will be recruited in the two mixed medical-
surgical ICUs of Hospital Israelita Albert Einstein in São
Paulo, Brazil. On a daily basis, the research team will
actively search the records and patient list for patients
admitted with a diagnosis of cirrhosis. Additionally, on-
call and horizontal care staff will be encouraged to recom-
mend eligible patients to the research team at any time.
The current recruitment rate is four patients per month
with an expected duration of recruitment of 42 months.
Recruitment rate will be monitored trimonthly.
Randomization, allocation and blinding
Allocation sequence with random numbers will be
computer-generated using random, varied size blocks and
stratification by severe renal failure (i.e., hemodialysis pro-
gram). The randomization sequence will be stored in indi-
vidually separated and sequentially numbered opaque,
sealed envelopes and kept secured in a locker with re-
stricted access (centralized at ICU pharmacy). After the
consent term is signed and coagulation tests collected, pa-
tients will be randomly assigned to study groups with an
allocation ratio of 1:1:1.
Allocation concealment will be preserved by holding
randomization sequence disclosure until the consent
term is signed and coagulation tests collected. Patients
Fig. 3 Restrictive blood transfusion protocol. INR international normalized ratio; FFP fresh frozen plasma
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will be enrolled by an on-call recruiter, and assignment
to intervention will be provided by an independent re-
searcher, who will be the only one to know which inter-
vention the patient will be assigned to. The research
subjects, central venous catheter inserter and outcome
assessors will be blinded to the assigned intervention
and bleeding will be assessed by the use of the HEME
tool [41] immediately after CVC and 24 h after the pro-
cedure. The catheter inserter is not directly responsible
for care of the patient included in the trial and will not
Fig. 4 The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) participant timeline in the POCKET trial. ROTEM®,
rotational thromboelastometry
Fig. 5 Study flowchart of the POCKET trial
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have access to the patient’s chart. In case of major bleed-
ing or serious transfusion-related adverse reaction,
unblinding to the attending physician is anticipated.
Sample size calculation
We calculated the sample size based on the primary efficacy
endpoint. We assumed a transfusion rate of 90% in the
Coagulogram-based group (i.e., control group) [11] and an
absolute risk reduction of 25% for the Thromboelastometry-
based and Restrictive groups. Using a study power of 0.80
and alpha of 0.05, we need n= 43 patients per group. The
sample size was adjusted for multiple comparisons
(additional increase of 20%, n= 8 per group) (Coagulogram-
based versus Thromboelastometry-based, Coagulogram-
based versus Restrictive, and Thromboelastometry-based
versus Restrictive) according to Witte et al. [43]. To account
for loss to follow-up, we have added 10% (n = 4) more pa-
tients to the adjusted sample size. The final required sample
will be 55 patients per group (total estimated sample size of
165 patients).
Data collection, monitoring and interim analysis
Trained researchers will be responsible for data collec-
tion. The principal investigator (PI) will be responsible
for double-checking the collected data and input data
into the study database. The quality of data will be guar-
anteed by locking the variables’ input range and random
checking for quality 5% of patient data at each interim
analysis and final analysis database.
The collected data will include age, race, gender,
weight, hospital and ICU admission dates, main ICU
diagnosis, cirrhosis etiology, transplant list status, co-
morbidities, Simplified Acute Physiology Score (SAPS 3)
[44], Sequential Organ Failure Assessment (SOFA) score
[45], Model for End-stage Liver Disease (MELD) score
[46], transfusion of blood products in the previous 24 h
and 24 h after CVC, procedure time, procedure
indication, catheter type, number of attempts, insertion
site, inserter, elective/emergency insertion, hemoglobin,
hematocrit, PT, aPTT, platelet count, serum fibrinogen,
ionized calcium, pH, peripheral temperature, ROTEM®
parameters (CT, CFT, α angle, MCF and A10), type and
quantity of transfused blood products for the procedure,
adverse events related to the procedure and transfusion,
when indicated, length of ICU and hospital stay and
mortality at day 28.
An independent Data Safety Monitoring Board
(DSMB) will conduct two interim analyses after the en-
rollment of 55 and 110 participants. The Lan-DeMets
alpha spending function method will be used to
determine statistical differences between groups [47].
After DSMB assessment, a report will be generated
recommending whether the trial should continue or stop
due to efficacy or harm. The final decision to stop the
trial will be held by the PI together with the POCKET
Trial Investigators. An independent audit will be
conducted every 6 months after recruitment of the first
patient. Every serious adverse event will be immediately
reported to the Ethics Committee and the DSMB, and
minor adverse events will be enlisted and periodically
released. Every protocol amendment will be subject to
approval from the local Ethics Committee.
Statistical analysis plan
All analyses will be performed as intention-to-treat. Cat-
egorical variables will be summarized as absolute and
relative frequencies. Normality will be tested with the
Kolmogorov-Smirnov test. Accordingly, continuous vari-
ables with normal distribution will be summarized as
mean ± SD, or median and interquartile range (IQR) in
case of non-normal distribution.
Comparisons between groups of continuous variables
will be performed with one-way analysis of variance
(one-way ANOVA) followed by Tukey’s test for multiple
comparisons (for normally distributed variables), or the
Kruskal-Wallis test followed by the Mann-Whitney U
test (for non-normally distributed variables). Proportions
between groups will be analyzed with the chi-square test
or Fisher’s exact test, as appropriate.
All binary outcomes will be analyzed using a general-
ized linear model with binomial distribution and logit
link function followed by pairwise comparisons adjusted
by Bonferroni correction for multiple comparisons. Pair-
wise comparisons will be presented as odds ratio (OR)
along with 95% confidence interval (95% CI), which will
be calculated by logistic regression.
A survival curve will be performed with the Kaplan-
Meier estimator and the log-rank test will be used to
compare groups. To assess time-to-event (28-day
mortality), an unadjusted Cox proportional hazards re-
gression model will be performed. The hazard ratio (HR)
with its respective 95% CI will be reported.
Prespecified subgroup analysis for the primary out-
come will be presented as a Forest plot, and will include
the presence of hypothermia (<35 °C), SAPS 3 score
(≥50 points) and MELD score (≥25 points). Interaction
between groups and each covariate will be assessed by
multivariate logistic regression.
Two-tailed tests will be used and when p < 0.05, the
test will be considered statistically significant. To ac-
count for multiple comparisons (Coagulogram-based
versus Thromboelastometry-based, Coagulogram-based
versus Restrictive and Thromboelastometry-based versus
Restrictive), the α level will be adjusted to 0.0167.
We will make maximum effort to reduce missing data.
We will use the multiple imputation method to handle
missing data when necessary. The Statistical Package for
the Social Sciences version 22.0 (IBM Inc., Chicago, IL,
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USA) will be used for statistical analyses. GraphPad
Prism version 6.07 (GraphPad Software Inc., La Jolla,
CA, USA) will be used for graph plotting.
Costs analysis
Transfusion and laboratory test costs will be assessed.
For the analysis of the costs of laboratory tests, we will
include the total cost of the test(s) (i.e., ROTEM® or
SCTs), which will guide the blood transfusion. The unit
cost information regarding blood products and coagula-
tion tests will be obtained from the blood bank and main
laboratory of Hospital Israelita Albert Einstein.
Ethics
The study was designed in accordance to the Declar-
ation of Helsinki. The Hospital Israelita Albert Einstein
Ethics Committee approved the study on 12 August
2014 (reference number: 734824). Recruitment of partic-
ipants started in September 2014 and is currently
ongoing. The study was registered at ClinicalTrials.org
(identifier: NCT02311985) on 3 December 2014. The re-
search team will release the study results in scientific
media regardless of their final results.
A trained research team member will obtain the in-
formed consent term from the research subject or their
next of kin. A deferred informed consent term will be
applied in case of emergency CVC when the patient
lacks clinical condition and no next of kin is immedi-
ately available. In this case, the definitive informed con-
sent must be obtained within 24 h after the procedure.
The participants may leave the study at any time with
no treatment disadvantage. All study information will be
kept secured with limited access. The patient database
will be password-protected and patients will be identi-
fied by trial ID numbers. A translated copy of the In-
formed Consent Form is available (see Additional file 2).
Discussion
Our trial is designed to compare three protocols to guide
transfusion of blood components prior to CVC in critic-
ally ill patients with chronic liver failure. We hypothesized
that restricted and thromboelastometry-guided transfu-
sion protocols would be safe and significantly reduce em-
pirical transfusion of blood products in cirrhotic critically
ill patients. By reducing transfusion rates, these strategies
would also reduce transfusion-related complications and
costs. This would help to provide quality evidence for re-
duction of empirical transfusion of critically ill patients
with coagulopathy in clinical practice.
One main focus of our trial is that the transfusion pro-
tocols used are based on a comprehensive assessment of
coagulation, which includes the contribution of coagula-
tion factors, platelets and fibrinogen. Most randomized
trials published so far have relied on a specific aspect of
coagulation and a specific blood product transfusion
(e.g., FFP transfusion according to PT/INR) [48, 49].
Furthermore, fibrinogen is one of the most important
coagulation factors [50], and we believe that including
the evaluation of hypofibrinogenemia or dysfibrinogen-
emia would result in a more detailed understanding of
coagulation status and, therefore, help in further preven-
tion of bleeding. Additionally, we will use wide inclusion
criteria, accounting for emergency insertions, active
bleeding and use of antiplatelet aggregation agents mak-
ing the case-mix of patients more similar to critical care
practice.
We considered the use a restrictive blood transfusion
protocol to be of vital importance. Several series of ob-
servational studies that included patients with coagulop-
athy have shown that experienced inserters have low
complication rates in different populations of patients
with coagulopathy, even when no blood transfusion is
performed prior to the procedure [51–55]. A large meta-
analysis showed that real-time ultrasound guidance for
CVC significantly reduced failure to obtain central ven-
ous access, arterial puncture, hematoma formation and
hemothorax by 82%, 75%, 70% and 90%, respectively,
when compared to using anatomical landmark guidance
[56]. Those positive effects are extended to hemodialysis
catheters [57]. Furthermore, the use of real-time ultra-
sound guidance increases the success rate in the first at-
tempt [6]. These may reduce complication rates to a
minimum, even in patients with coagulopathy. We be-
lieve that blood product transfusion is frequently exces-
sive when a trained inserter in ultrasound-guided CVC
performs the procedure.
We have foreseen some potential issues for this trial. One
major issue is not to complete the necessary recruitment re-
quired due to low adhesion by practicing physicians and the
single-center setting. Every practice-changing protocol may
be prone to resistance and low adhesion, mainly by cultural
environment. Conversely, we will use broad inclusion cri-
teria and health care provider sensitization campaigns to try
to overcome this potential drawback. Another issue is an
early trial stop due to either efficacy or harm. We pro-
grammed two interim analyses when one third and two
thirds of patients are enrolled, respectively. Since few ran-
domized clinical trials have assessed restrictive blood trans-
fusion protocols prior to invasive procedures in critically ill
patients with cirrhosis, we will follow the research subjects
closely for adverse events.
This trial has potential limitations. Single-center trials
may have a potential limited external validity [58] and
may overestimate treatment effect when compared to
multicenter trials [59]. The results from single-center tri-
als must be applied with caution in daily clinical prac-
tice. This trial is not adequately powered to address
transfusion-related complications, which ranges from
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one event in hundreds to thousands of blood transfu-
sions [60]. Accordingly, our primary objective is to
evaluate the feasibility and safety of strategies that use a
more detailed overview of coagulation status or restrict-
ive transfusion of blood components in critically ill pa-
tients with cirrhosis.
The results from this trial will help to develop multi-
center randomized clinical trials to assess blood product
transfusion prior to invasive procedures in critically ill
patients with suspected coagulopathy. Our intention is
to provide good-quality scientific evidence for transfu-
sion of blood products in patients with coagulopathy, re-
ducing excessive and empirical use of blood and costs in
the health care system.
Trial status
This trial is currently ongoing (recruitment phase).
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